From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

OptiBiotix – long-winded “Strategic and commercial update”, but various positives suggest still a Strong Buy with target price increased

By Tom Winnifrith & Steve Moore | Wednesday 28 February 2024


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


OptiBiotix Health (OPTI) has issued a “Strategic and commercial update” announcement. There are various positives in the long-winded announcement and the shares have currently responded more than 11% higher to 25p, but that’s still below levels of even early this month and we’d have preferred a much more to-the-point announcement of financials and orders news. However, having spoken to CEO Stephen O’Hara, we believe significant progress is being made on those to mean significant potential from the current £22.8 million market capitalisation.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

Gold

Sprott bullish on gold

 

SOS

Sosandar: when is the warning?

 

SCGL

Evil Banksta: TW schoolboy error

 

ARB

Worthless Argo what news Helios?

Sunday »

Bearcast

Tom Winnifrith Bearcast: macrobabble calls

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 18:20:13